-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Cyclerion Therapeutics (NASDAQ:CYCN) Stock Price Down 6.4%
Cyclerion Therapeutics (NASDAQ:CYCN) Stock Price Down 6.4%
Shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Rating) fell 6.4% during trading on Monday . The stock traded as low as $0.78 and last traded at $0.82. 161,207 shares changed hands during mid-day trading, a decline of 20% from the average session volume of 200,444 shares. The stock had previously closed at $0.88.
Cyclerion Therapeutics Stock Performance
The company has a market cap of $35.66 million, a PE ratio of -0.75 and a beta of 2.05. The company's 50-day simple moving average is $0.60 and its 200 day simple moving average is $0.71.
Get Cyclerion Therapeutics alerts:Cyclerion Therapeutics (NASDAQ:CYCN – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.11. Cyclerion Therapeutics had a negative net margin of 2,551.69% and a negative return on equity of 149.84%. Analysts forecast that Cyclerion Therapeutics, Inc. will post -1.16 EPS for the current year.
Hedge Funds Weigh In On Cyclerion Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mackenzie Financial Corp purchased a new position in Cyclerion Therapeutics in the 1st quarter valued at approximately $28,000. Prudential Financial Inc. acquired a new stake in shares of Cyclerion Therapeutics in the 2nd quarter valued at $29,000. Jane Street Group LLC acquired a new stake in shares of Cyclerion Therapeutics in the 2nd quarter valued at $32,000. Prelude Capital Management LLC raised its holdings in shares of Cyclerion Therapeutics by 29.2% in the 1st quarter. Prelude Capital Management LLC now owns 100,255 shares of the company's stock valued at $111,000 after purchasing an additional 22,672 shares in the last quarter. Finally, Trustcore Financial Services LLC raised its holdings in shares of Cyclerion Therapeutics by 47.7% in the 1st quarter. Trustcore Financial Services LLC now owns 292,645 shares of the company's stock valued at $325,000 after purchasing an additional 94,539 shares in the last quarter. Hedge funds and other institutional investors own 48.34% of the company's stock.About Cyclerion Therapeutics
(Get Rating)
Cyclerion Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults.
Featured Articles
- Get a free copy of the StockNews.com research report on Cyclerion Therapeutics (CYCN)
- CrowdStrike Selloff: It's Time For Investors to Strike
- Pure Storage is a Steady Eddie Growing Storage Play
- Tesla Shares Are Sliding, Here's Why
- Insiders And Institutions Buy Fastenal, An Aristocrat To Be
- Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Rating) fell 6.4% during trading on Monday . The stock traded as low as $0.78 and last traded at $0.82. 161,207 shares changed hands during mid-day trading, a decline of 20% from the average session volume of 200,444 shares. The stock had previously closed at $0.88.
在周一的交易中，周期治疗公司(纳斯达克代码：CYCN-GET评级)的股价下跌了6.4%。该股最低交易价格为0.78美元，最后报0.82美元。午盘交易中，161,207股股票易手，较200,444股的平均成交量下降了20%。该股此前收盘价为0.88美元。
Cyclerion Therapeutics Stock Performance
周期标准治疗公司股票表现
The company has a market cap of $35.66 million, a PE ratio of -0.75 and a beta of 2.05. The company's 50-day simple moving average is $0.60 and its 200 day simple moving average is $0.71.
该公司市值为3,566万美元，市盈率为-0.75，贝塔系数为2.05。该公司的50日简单移动均线切入位在0.60美元，200日简单移动均线切入位在0.71美元。
Cyclerion Therapeutics (NASDAQ:CYCN – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.11. Cyclerion Therapeutics had a negative net margin of 2,551.69% and a negative return on equity of 149.84%. Analysts forecast that Cyclerion Therapeutics, Inc. will post -1.16 EPS for the current year.
周期治疗公司(纳斯达克代码：CYCN-GET Rating)上一次发布季度收益报告是在11月3日星期四。该公司公布了本季度每股收益(0.24美元)，比普遍预期的(0.35美元)高出0.11美元。周期治疗公司的净利润率为负2551.69%，净资产回报率为负149.84%。分析师预测，Cyclarie治疗公司本年度的每股收益将达到1.16美元。
Hedge Funds Weigh In On Cyclerion Therapeutics
对冲基金对周期治疗公司的看法
About Cyclerion Therapeutics
关于周期疗法
(Get Rating)
(获取评级)
Cyclerion Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults.
周期治疗公司是一家临床阶段的生物制药公司，致力于治疗严重中枢神经系统(CNS)疾病的药物的发现、开发和商业化。它的主要候选产品是CY6463，这是一种中枢神经系统穿透性、可溶性鸟苷环化酶(SGC)刺激剂，正处于IIa期试验，用于治疗线粒体脑肌病、乳酸酸中毒和中风样发作，以及有血管病变的阿尔茨海默病；以及成人精神分裂症的1期试验。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Cyclerion Therapeutics (CYCN)
- CrowdStrike Selloff: It's Time For Investors to Strike
- Pure Storage is a Steady Eddie Growing Storage Play
- Tesla Shares Are Sliding, Here's Why
- Insiders And Institutions Buy Fastenal, An Aristocrat To Be
- Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
- 免费获取StockNews.com关于周期疗法(Cycn)的研究报告
- CrowdStrike抛售：投资者罢工的时候到了
- Pure Storage是稳步增长的存储业务
- 特斯拉股价下滑，原因如下
- 内部人士和机构收购Fastenal，成为未来的贵族
- 大地块是不是正在酝酿中的下一个床上沐浴和超越灾难？
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《环素疗法日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Cyclarion治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧